Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Rovadicitinib by Sino Biopharmaceutical for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
Rovadicitinib is under clinical development by Sino Biopharmaceutical and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase...